847818-70-6

Basic information

• Product Name: 1-Ethyl-1H-pyrazole-4-boronic acid, pinacol ester
• Synonyms: 1-ethyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;3-hydroxy-2,3-dimethylbutan-2-yl hydrogen (1-ethyl-1H-pyrazol-4-yl)boronate;1-Ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole;1-Ethyl-1H-pyrazole-4-boronic acid, pinacol ester;1-Ethylpyrazole-4-boronic Acid Pinacol Ester;1-Ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1H-Pyrazole, 1-ethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-
• CAS NO: 847818-70-6
• Molecular Formula: C₁₁H₁₉BN₂O₂
• Molecular Weight: 222.1
• Mol File: 847818-70-6.mol
• Article Data: 20

Chemical Properties

• Melting Point: 44-49°C
• Boiling Point: 322.6 °C at 760 mmHg
• Flash Point: 148.9 °C
• Appearance: /
• Density: 1.04 g/cm³
• Vapor Pressure: 0.000522mmHg at 25°C
• Refractive Index: 1.503
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.11±0.10(Predicted)
• CAS DataBase Reference: 1-Ethyl-1H-pyrazole-4-boronic acid, pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Ethyl-1H-pyrazole-4-boronic acid, pinacol ester(847818-70-6)
• EPA Substance Registry System: 1-Ethyl-1H-pyrazole-4-boronic acid, pinacol ester(847818-70-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 847818-70-6(Hazardous Substances Data)

Usage

General Description

1-Ethyl-1H-pyrazole-4-boronic acid, pinacol ester is a boronic acid derivative that is commonly used in organic synthesis for the formation of carbon-carbon and carbon-heteroatom bonds. It is a pinacol ester, meaning that it contains a pinacol group, which is often used to enhance the stability and reactivity of boronic acid compounds. This chemical is often utilized as a building block in the preparation of pharmaceuticals, agrochemicals, and materials, due to its ability to undergo various coupling reactions with organic substrates. Additionally, its unique structure allows it to participate in Suzuki-Miyaura cross-coupling reactions, making it a valuable tool in the field of organic chemistry.

InChI:InChI=1/C11H19BN2O2/c1-6-14-8-9(7-13-14)12-15-10(2,3)11(4,5)16-12/h7-8H,6H2,1-5H3

Upstream product

• 76-09-5 2,3-dimethyl-2,3-butane diol 
• 847818-56-8 (1-ethyl-1H-pyrazol-4-yl)boronic acid 
• 73183-34-3 bis(pinacol)diborane 
• 71229-85-1 4-bromo-1-ethyl-1H-pyrazole 
• 1022151-21-8 3-{4-[6-(6-methyl-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl)-quinolin-3-yl]-pyrazol-1-yl}-azetidine-1-carboxylic acid tert-butyl ester 
• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 75-03-6 ethyl iodide 
• 74-96-4 ethyl bromide 
• 74-88-4 methyl iodide 
• 425-75-2 trifluoromethanesulfonic acid ethyl ester 

Downstream Products

• 1430725-01-1 N-(3-(5-(1-ethyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrrol-1-yl)phenyl)acetamide 
• 1430728-84-9 3-(5-(1-ethyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrrol-1-yl)aniline 
• 1430725-02-2 N-(3-(5-(1-ethyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrrol-1-yl)phenyl)ethanesulfonamide 
• 1403396-84-8 (8R)-8-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3-{1-[4-(1-ethyl-1H-pyrazol-4-yl)phenyl]cyclopropyl}-8-methyl-5,6,8,9-tetrahydro[1,2,4]triazolo[4,3-d][1,4]thiazepine 
• 1578247-11-6 4-(1-ethyl-1H-pyrazol-4-yl)-2-methoxyaniline 
• 1578244-52-6 8-(1-ethyl-1H-pyrazol-4-yl)-N-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyrido[3,4-d]pyrimidin-2-amine 
• 1590409-31-6 C₁₉H₁₆F₃N₅O₂ 
• 1620291-57-7 N-((5-((2-(1-ethyl-1H-pyrazol-4-yl)phenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)imidazo[1,2-a]pyridine-6-carboxamide 
• 847818-56-8 (1-ethyl-1H-pyrazol-4-yl)boronic acid 
• 75702-85-1 1-ethyl-1H-pyrazol-4-ol 

Relevant articles and documents

PESTICIDALLY-ACTIVE CYANAMIDE HETEROCYCLIC COMPOUNDS

A compound of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.

Development of novel amide–derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) is a potential target in Alzheimer's disease (AD) because of the established correlation between its over-expression and generation of neurofibrillary tangles (NFT) as well as the accumulation of amyloid plaques. However, the use of Dyrk1A inhibitors requires a high degree of selectivity over closely related kinases. In addition, the physicochemical properties of the Dyrk1A inhibitors need to be controlled to enable CNS permeability. In the present study, we optimized our previously published 2,4-bispyridyl thiophene class of Dyrk1A inhibitors by the synthesis of a small library of amide derivatives, carrying alkyl, cycloalkyl, as well as acidic and basic residues. Among this library, the cyclopropylamido modification (compound 4b) was identified as being highly beneficial for several crucial properties. 4b displayed high potency and selectivity against Dyrk1A over closely related kinases in cell-free assays (IC50: Dyrk1A = 3.2 nM; Dyrk1B = 72.9 nM and Clk1 = 270 nM) and inhibited the Dyrk1A activity in HeLa cells with high efficacy (IC50: 43 nM), while no significant cytotoxicity was observed. In addition, the cyclopropylamido group conferred high metabolic stability and maintained the calculated physicochemical properties in a range compatible with a potential CNS activity. Thus, based on its favourable properties, 4b can be considered as a candidate for further in vivo testing in animal models of AD.

SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO

Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts and /V-oxides thereof, wherein X1, X2, Z1, Z2, the ring system denoted by "a", R1, A1A, L1B, A1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein disrupt the elF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.